<DOC>
	<DOCNO>NCT00801957</DOCNO>
	<brief_summary>Seven-month study pediatric patient ( 2-11 year ) moderate severe AD consider benefit vaccination prevent invasive disease cause Neisseria meningitides serogroup C .</brief_summary>
	<brief_title>Equivalence Response Vaccination Tacrolimus Ointment Steroid Ointment Regimen Children With Atopic Dermatitis</brief_title>
	<detailed_description>At week 1 visit , patient vaccinate protein-conjugated vaccine meningitis . All patient receive challenge month 6 visit low dose meningo polysaccharide vaccine . A control group healthy subject ( suffer atopic dermatitis ) receive vaccination challenge dose .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Butyric Acid</mesh_term>
	<mesh_term>Hydrocortisone-17-butyrate</mesh_term>
	<criteria>Patients moderate severe atopic dermatitis need treatment Patients require vaccination prevent invasive disease cause Neisseria meningitidis serogroup C Patients know hypersensitivity macrolides , tacrolimus component vaccine Patients acute severe febrile illness , genetic epidermal barrier defect Netherton 's syndrome generalize erythroderma , skin infection affect treated area Patients already receive meningo polysaccharide conjugate vaccine meningitis</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>meningitis</keyword>
	<keyword>vaccination</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>steroid</keyword>
	<keyword>equivalence response</keyword>
	<keyword>meningococcal vaccine</keyword>
</DOC>